Therapeutic vaccine for Hepatitis B virus (HBV) using the HBV core antigen
US11883488B2 · kind B2 · utility
0Cited by
2References
21Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 15, 2022 |
| Grant date | Jan 30, 2024 |
| Priority date | — |
| Expiry date | Apr 15, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2730/10171
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided herein are compositions of CD1280 binding proteins and a Hepatitis B virus core antigen (HBcAg) and/or a Hepatitis B virus E antigen (HBeAg), or antigenic fragments or mutants thereof, attached to the CD180 binding protein, and methods for using the compositions to treat or limit the development of hepatitis-B virus (HBV)-related disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.